Search En menu ClientConnect
Top 5 search results See all results Advanced search
Top searches
Most visited pages
    Reference: 20160789
    Release date: 8 December 2016

    Promoter – Financial Intermediary

    Acceptable Corporate(s)



    Capital expenditure investments related to medical technology


    The project concerns the investment in a new parenteral unit in order to produce large volume parenteral solutions and small volume parenteral solutions.


    Proposed EIB finance (Approximate amount)

    EUR 20 million

    Total cost (Approximate amount)

    EUR 42 million

    Environmental aspects

    The project falls under Annex II of Environmental Impact Assessment (EIA) Directive 2011/92/EU (implementation of an industrial facility for the production of pharmaceutical products). The project has been screened by the competent authorities and the EIA is currently under public consultation. Full environmental details will be assessed during the appraisal.


    The promoter is a private company not operating in the utilities sector and is thus not covered by EU directives on procurement.


    Signed - 30/06/2017


    Before financing approval by the Board of Directors, and before loan signature, projects are under appraisal and negotiation. The data provided on this page is therefore indicative and cannot be considered to represent official EIB policy (see also the Explanatory notes).

    Related tags

    Portugal Industry